Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

at the Institut Jules Bordet in Brussels, Belgium.  "The high confirmed objective response rate continues to show that NKTR-102 is one of the most active single agents in this disease.  This is particularly evident given the number of patients with dramatic reduction in lung and liver metastases."

The confirmed ORR was maintained in poor prognosis and heavily pre-treated subsets within the study, including patients previously treated with anthracycline/taxane/capecitabine: 33% (5/15); patients with metastatic triple-negative breast cancer: 39% (7/18); and patients with visceral disease: 29% (17/58).  As of October 26, 2010, preliminary median progression-free survival (PFS) for all patients was 20 weeks. [Efficacy Tables, Figures A - C]

"We are in critical need of effective new therapeutic options whose mechanism of action is different from those already available for women with metastatic breast cancer," continued Dr. Awada.  "This is especially true for those patients whose disease has progressed despite treatment with anthracyclines and taxanes.  NKTR-102 is emerging as an important investigational treatment in metastatic breast cancer and has the potential to be the first topoisomerase 1 inhibitor in this disease.  NKTR-102 should enter Phase 3 clinical studies as quickly as possible."

Patients treated in the single-agent NKTR-102 study had a median of two lines of prior cytotoxic treatments for metastatic disease.  Seventy-three percent (51/70) of the patients received neoadjuvant and/or adjuvant therapy and 87% (61/70) had visceral disease.  

"NKTR-102 is quickly emerging as a very important potential new drug in the fight against cancer," said Lorianne Masuoka, M.D., Senior Vice President and Chief Medical Officer.  "The drug has consistently high response rates as a single-agent in multiple Phase 1 and 2 clinical studies to-date, including our study in platinum-resistant ova
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... analysis of Centers for Medicare and Medicaid Services, (CMS) ... percent of seniors chose lower-cost preferred pharmacy plans that ... The findings were released by Drug Channels . ... of Medicare Part D," said Pharmaceutical Care Management Association ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. ... Biotechnology, Inc. for the compounding, packaging and distributing of its ... the United States . ... of compounding naltrexone tablets in various strengths for individual patients ...
(Date:1/23/2015)... 23, 2015  Now available for sale, The Armor1 Ankle ... prevents ankle sprains by cushioning the ankle from an ... around the outside of any shoe type and allows ... still offering protection against sprains. With customers in physical ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2
... 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... of medical devices worldwide, announced today an agreement to ... Technical Development Co. Ltd. The terms of the transaction ... Mindray,s financial statements. Founded in 2004 and ...
... Nev., Feb. 28, 2011 PDL ... financial results for the fourth quarter and full year ended ... were $345.0 million, compared to $318.2 million in 2009.  Excluding ... royalty revenues for 2010 increased 30 percent over 2009.  For ...
Cached Medicine Technology:Mindray Medical to Acquire a Controlling Stake in Shenke Medical 2Mindray Medical to Acquire a Controlling Stake in Shenke Medical 3Mindray Medical to Acquire a Controlling Stake in Shenke Medical 4PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 2PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 3PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 4PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 5PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 6PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 7PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 8PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 9PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 10
(Date:1/22/2015)... Deer Path of Huntley -- a BMA affordable assisted ... 3 p.m. to 4 p.m. on Feb. 13. , The community, ... adults with physical disabilities between the ages of 22 and 64. ... and sweetheart-themed karaoke. , For more information about the event or ...
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has ... the business is showing its latest designs of wedding dresses ... to the company’s CEO, all the fresh new products are ... discounts, up to 80% off. All the clothes from LunaDress ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release ... for kids with cancer. The Chemo Duck App, available on iTunes ... enjoyable games to help children of all ages living with cancer ... keep kids entertained, educated and at ease while waiting for clinic ...
(Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... Breast cancer patients treated with intensity modulated radiation therapy ... a lower incidence of acute or chronic toxicities, according ... ( PRO ), the official clinical practice journal of ... constantly conducting studies to determine the most effective breast ...
... By Alan Mozes HealthDay Reporter , MONDAY, March ... procedures to standard diabetes treatments contends that surgery is more ... finding stems from two years of tracking 60 severely obese ... ages of 30 and 60. One-third of the patients were ...
... on 31 March when the ship and crew reach Lorient, ... across all the world,s major oceans to sample and investigate ... Karsenti in an editorial published today in Molecular Systems ... yet we know very little about the distribution of marine ...
... HealthDay Reporter , MONDAY, March 26 (HealthDay News) -- ... lowered LDL cholesterol levels in patients with high cholesterol ... treatment could help lower levels of "bad" cholesterol for ... the commonly prescribed cholesterol-lowering drugs known as statins. It ...
... (HealthDay News) -- Antibiotics can prolong cystic fibrosis patients, ... in their lungs, a new, small study suggests. ... not prove, that the current standard of aggressive antibiotic ... the best approach. It,s common to use antibiotics ...
... HealthDay Reporter , MONDAY, March 26 (HealthDay News) -- ... that people who eat chocolate regularly are somewhat skinnier than ... don,t prove that chowing down on chocolate will melt off ... for the modest difference in body mass, or it might ...
Cached Medicine News:Health News:IMRT reduces risk of side effects in breast cancer patients 2Health News:Weight-Loss Surgeries May Beat Standard Treatments for Diabetes 2Health News:Weight-Loss Surgeries May Beat Standard Treatments for Diabetes 3Health News:Weight-Loss Surgeries May Beat Standard Treatments for Diabetes 4Health News:TARA OCEANS completes 60,000-mile journey to map marine biodiversity 2Health News:New Injection Might Lower Tough-to-Treat Cholesterol 2Health News:New Injection Might Lower Tough-to-Treat Cholesterol 3Health News:Should Cystic Fibrosis Patients Get So Many Antibiotics? 2Health News:Does Chocolate Help You Stay Slim? 2Health News:Does Chocolate Help You Stay Slim? 3
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... tricompartmental total knee prosthesis stems from many ... design and manufacturing technologies have been used ... as well as a favorable pressure distribution ... keep wear to a minimum. The inherent ...
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
Medicine Products: